Redx to Get $5 Mln on Tumor Drug Milestone With US Regulator [MarketWatch]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: MarketWatch
Food and Drug Administration, triggering a milestone payment of $5 million from Jazz Pharmaceuticals PLC. The London-listed drug discovery-and-development company said the payment stemmed from an agreement in which Jazz acquired Redx's pan-RAF inhibitor program. The company said the payment came on top of a previous $6.5 million payment already received, and that it remained entitled "To development, regulatory and commercial milestone payments as well as incremental tiered royalties in mid-single digit percentages, based on any future net sales." The company said JZP815 was an investigational preclinical stage pan-RAF kinase inhibitor. A kinase inhibitor refers to a substance which blocks a type of enzyme known as kinase, and are helpful in keeping cancer cells from growing. Shares at 0822 GMT were up 4.70 pence, or 7.7%, at 65.50 pence. Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024PR Newswire
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024PR Newswire
- Acute Lymphocytic Leukemia (ALL) Pipeline Landscape Report 2024: Comprehensive Insights About 250+ Companies and 250+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off [Seeking Alpha]Seeking Alpha
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.MarketBeat
JAZZ
Earnings
- 2/28/24 - Beat
JAZZ
Sec Filings
- 4/9/24 - Form 4
- 3/8/24 - Form 4
- 3/7/24 - Form 4
- JAZZ's page on the SEC website